As noted earlier, the ALK inhibitors crizotinib and LDK378 are currently in development for EML4-ALK NSCLC though at present, only crizotinib has been shown to be effective in treating this small subset of patients with a ROS1 translocation [54]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.